NCT04680377View on ClinicalTrials.gov

Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

RecruitingOBSERVATIONAL
Enrollment

44

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
NSCLC, Stage IIILocally Advanced Lung Carcinoma
Trial Locations (2)

66205

RECRUITING

The University of Kansas Cancer Center, Westwood Campus, Kansas City

02905

NOT_YET_RECRUITING

Rhode Island Hospital, Brown University, Providence

All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

lead

Jun Zhang, MD, PhD

OTHER